Infliximab for Eczema: Why an Early Improvement Did Not Become a Sustained Group Response
The first good weeks do not answer the whole question
When severe eczema improves soon after a treatment begins, the practical question becomes whether the improvement will last. A short headline may emphasize the early change while leaving out later loss of benefit. An older infliximab pilot is useful because it followed patients beyond the initial response and reported a less encouraging maintenance experience.
Nine adults, one center, no placebo group
The 2005 primary report followed nine people with moderate or severe atopic dermatitis resistant to conventional care. The accessible methods describe six men and three women aged 19–61. It was an open prospective single-center study, with planned infusions from baseline through week 38 and follow-up through week 46. These features make it exploratory, rather than a randomized comparison of treatment choices.
| Evidence detail | Interpretation |
|---|---|
| Early group score | Mean EASI decreased from 22.5 at baseline to 10.6 at week two; p = .03. |
| What that number means | A change in a group-average severity score, not proof that every person improved by the same amount. |
| Later course | The initial improvement was not sustained through maintenance at group level. |
| End of follow-up | The abstract reports excellent clinical response in only two patients with severe disease by week 46. |
Do not turn two long responders into a dependable success rate
Nine people cannot supply a precise prediction for the next patient. With no control group, changes in eczema activity, other care and observation effects are difficult to separate from a medicine's contribution. The two late responders do not erase loss of benefit in the rest of the study. Our study interpretation guide helps distinguish an early average score change from a durable response probability.
A proper treatment review needs a timeline: when benefit began, whether it faded between visits and why treatment was continued or stopped. That is especially relevant when an intervention requires infusion visits. A temporary improvement can still matter to a patient, but it should not be advertised as established long-term control.
The current Remicade label does not establish eczema use
Current U.S. Remicade prescribing information lists particular bowel, joint and plaque-psoriasis indications, not atopic dermatitis. It includes boxed warnings about serious infections and malignancy. Approval in another inflammatory disease does not validate an eczema regimen. Do not stop a prescription for another diagnosis because of this article; review new symptoms and treatment questions with its prescriber.
Define success before the next treatment change
Ask which benefit should persist and when it will be reassessed. Track itch separately from rash severity, the ability to complete daily tasks and sleep disruption. These records can distinguish a brief good week from useful ongoing control. Discuss alternatives using current AAD eczema guidance, rather than treating this small historical pilot as a present-day recommendation.
Keep cosmetic moisture care in its own role
Dr. Arsy #003 4 oz moisturizer offers cosmetic hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema, and none of the studies described here tested #003. The sports editorial image is a lifestyle illustration, not evidence of medicine-like effects. Ask a clinician about a new product for a child or for actively inflamed skin.
A related treatment-evidence question
For another older systemic study, compare interferon gamma's randomized trial and current label; its controlled design answers a different question from this pilot.